Circulatory and renal control by prostaglandins and renin in low cardiac output in dogs.
Changes of neurohumoral factors including vasodilatory prostaglandins (PGs) were investigated in an experimental model of moderate low-cardiac-output status induced by rapid right ventricular pacing (240 beats/min). After 7 days of pacing, we studied the response of renal, hormonal, and hemodynamic parameters to cyclooxygenase inhibition by indomethacin and the effects of the renin system by converting-enzyme blockade in addition to the inhibition of PG synthesis. Lowering cardiac output increased plasma levels of norepinephrine and atrial natriuretic peptide. Plasma renin concentration was suppressed, despite a fall in cardiac output and blood pressure and a stimulation of sympathetic nerve activity. Urinary excretion of PGE2 was increased (P less than 0.04); plasma levels of PGE2 and 6-keto-PGF1 alpha were unchanged as measured in blood from the renal vein, pulmonary artery, and aorta. During low cardiac output, we found a significant decrease of glomerular filtration rate, whereas renal blood flow and renal and peripheral vascular resistances were unchanged. Administration of indomethacin decreased plasma and urinary PGs significantly, markedly reduced renal blood flow, and increased renal vascular resistance without affecting peripheral vascular resistance. The additional blockade of the renin-angiotensin system by captopril showed mainly a vasodilator effect on peripheral arterial resistance vessels, resulting in an increase of cardiac output. Our results suggest that, in moderate low-cardiac-output status, renal blood flow is maintained by renal vasodilator PGs, which counterbalance vasoconstrictor mechanisms like the activated sympathetic nerve activity. We indirectly showed the importance of angiotensin II in preserving glomerular filtration rate, which declines when renin secretion is suppressed, as it may be the case in moderate heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
Riegger
G A
GA
Medizinische Universitätsklinik, Würzburg, Federal Republic of Germany.
Elsner
D
D
Kromer
E P
EP
D000804:Angiotensin II / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D002303:Cardiac Output, Low / Q000503:physiopathology*; D004285:Dogs; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D007668:Kidney / Q000503:physiopathology*; D009638:Norepinephrine / Q000097:blood; D011453:Prostaglandins / Q000502:physiology*; D012079:Renal Circulation; D012084:Renin-Angiotensin System
D000806:Angiotensin-Converting Enzyme Inhibitors; D011453:Prostaglandins; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D009638:Norepinephrine; D007213:Indomethacin